Porton Advanced Solutions, a cell and gene therapy contract development and manufacturing organization (CDMO), has signed an agreement with Suzhou Royaltech Med Co., Ltd., to promote the establishment of microbial vectors used for gene therapy (MVGTs) and mRNA drug platform technology, as well as accelerate the R&D process of innovative biopharmaceuticals.

Porton Advanced provides an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and viable bacteria therapy. Suzhou Royaltech focuses on the development of vaccines for tumor immunotherapy with its proprietary technologies, and fast transition from clinical to market. Its R&D pipeline covers the attenuated non-integrated Listeria platform, mRNA platform, and cell therapy platform.

“We are very pleased to enter into this strategic collaboration with Royaltech,” said Yangzhou Wang, CEO of Porton Advanced. “The core management team of Royaltech is from the top pharmaceutical companies, with an average of 15 years of R&D and management experience and is advancing an internationally competitive R&D pipeline. Porton Advanced’s end-to-end gene and cell therapy CDMO platform with rich project experience and comprehensive quality system will help Royaltech with the development of Listeria and mRNA drugs, push its R&D pipeline in a quick, efficient manner, and accelerate the development and implementation of innovative drugs, so that good medicines can benefit the public earlier.”

Chun Xu, chairman of Royaltech, said, “As a biotech company, we are grateful to work with Porton Advanced, a very professional CDMO company, to jointly build a unique Listeria and mRNA tumor vaccine platform technology, and constantly develop leading tumor immunotherapeutic biological drugs in China and abroad.”